Cafer's Psychopharmacology


I'm finally putting the finishing touches on the book I've been working on for several years. 300 pages, 270 medication monographs of psychotropic medications, 1,000 pictures. Each medication monograph is a visual mnemonic to help you pair the trade name with the generic name of the drug. Each's medication's mnemonic character (think the Xyzal "Wise Owl" or Myrbetriq bladder character) also fits into a visual framework to help you learn/remember how drugs interact with each other, e.g., by induction/inhibition of cytochrome P450 enzymes. The book will be available on Amazon around July 2020. If any doctors are interested in reviewing a chapter or two (out of 26), I'd love to share a draft copy of the book. I'll be posting some of the content here, stay tuned. 

Now available:

 Cafer's Mood Stabilizers and Antiepileptics



































Comments











Post a Comment























Popular posts from this blog









Cenobamate (XCOPRI) visual mnemonics




















Image







Excerpt from  Cafer's Mood Stabilizers and Antiepileptics, available on Amazon Cenobamate (XCOPRI) “Cinnab on  Ex-co uple ” Pronunciation:  sen oh BAM ate / EX cop ree  ❖ Antiepileptic  ❖ GABA A  modulator  ❖ DEA Schedule V   FDA approved for:   ❖ Partial-onset seizures (adults)   Cenobamate (Xcopri) is the newest antiepileptic drug (AED) , released in 2020. There are some serious risks , side effects and kinetic drug/drug interactions.   Dosing is similar to lamotrigine (Lamictal), with a slow titration to a recommended dose  of 200 mg over 11 weeks . As with lamotrigine, maximum dose is 400 mg. The slow titration is necessary to avoid Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) , also known as multiorgan hypersensitivity. There were no cases of DRESS among over 1,000 patients with adherence to the slow titration schedule. Cenobamate shortens QT  interval and is contraindicated with Familial Short QT Syndrome. QTc interval under 300 is da...








Read more










Lithium




















Image







Excerpt from  Cafer's Mood Stabilizers and Antiepileptics Mood stabilizer      Neuroprotectant   FDA approved for: ❖ Acute mania     ❖ Bipolar disorder (maintenance) Used off-label for:     ❖ Depression     ❖ Suicidal ideation     ❖ Dementia     ❖ Alcoholism     ❖ Agitation     ❖ Headaches     ❖ Neutropenia     ❖ SIADH     ❖ Longevity  Lithium is the gold standard treatment for bipolar disorder. It is superior to all medications at preventing suicide, reducing risk 5-fold for individuals with recurrent unipolar depression and 6-fold for those with bipolar disorder (Tondo et al, 2016).  It works by several mechanisms that are not entirely understood.  Lithium is an element on the periodic table, classified as an alkali metal. Its atomic number is 3, making it the 3rd lightest element. Lithium was one ...








Read more










Lumateperone (Caplyta)




















Image







Available on Amazon:  Cafer's Mood Stabilizers and Antiepileptic Drugs        Lumateperone (CAPLYTA) Pronunciation:  luma TEP er ohn / cap LIE ta  “’Lum inated  Cap lighter” Antipsychotics are represented  with spooky mascots. Year of US release: 2020  ❖ Antipsychotic (SGA) ❖ D2 antagonist - ⇩DA ❖ 5-HT2A antagonist - ⇧DA ❖ Glutamate modulator  FDA-approved for:  ❖ Schizophrenia  Lumateperone is a new antipsychotic that purportedly modulates glutamate  in addition to the usual SGA mechanism of blocking D2 and 5-HT2A receptors. However, the official prescribing information does not mention glutamate, suggesting the FDA saw insufficient evidence for lumateperone being a first-in-class novel antipsychotic. It appears to be equally effective as risperidone (Risperdal) with fewer side effects other than sedation (Citrome, 2016).  Lumateperone’s D2 receptor occupancy is lower than most other antipsychotics. This means extrapyramidal side effects are unlikely. The other anti...








Read more